非药物治疗刺激性肠综合征的非药物治疗方法
Xiao Jing Wang1, Elyse Thakur2,3, Jordan Shapiro4
1Mayo Clinic Rochester, MN, USA Wang.xiao@mayo.edu.
概括
刺激性肠综合征 (IBS) 管理越来越依赖于非药物选择,如低FODMAP饮食和肠道导向催眠疗法. 本综述探讨了这些和IBS的其他补充疗法的证据.
科学领域:
- 胃肠病学 胃肠病学
- 肠-大脑相互作用障碍 肠-大脑相互作用障碍
背景情况:
- 刺激性肠综合征 (IBS) 是一种常见的慢性肠脑相互作用障碍.
- IBS显著影响生活质量,并造成全球经济成本.
- 复杂而异质的病理生理学需要不同的治疗方法.
研究的目的:
- 审查目前关于非药物IBS治疗的证据.
- 突出IBS饮食和行为疗法的进步.
- 讨论补充和新兴的IBS疗法.
主要方法:
- 对非药物IBS干预措施的文献综述.
- 对饮食疗法的证据分析 (例如,低FODMAP饮食).
- 评估大脑-肠道行为干预措施 (例如,催眠疗法,CBT).
主要成果:
- 非药物IBS治疗是主要临床指南的组成部分.
- 饮食和行为疗法显示出显著的疗效.
- 在获得和最佳实施这些疗法方面仍然存在挑战.
结论:
- 非药物IBS疗法至关重要,具有既定的饮食和行为选择.
- 对补充和新兴的IBS治疗方法的持续研究是有必要的.
- 改善基于证据的非药物治疗方法的获取和实施对于IBS患者的护理至关重要.
相关概念视频
Irritable Bowel Syndrome III: Medical and Nursing Management
166
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
166
Drugs for Treatment of Constipation-Predominant IBS
133
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
133
Drugs for Treatment of Diarrhea-Predominant IBS
147
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
147
Inflammatory Bowel Disease IV: Pharmacological Management
111
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
111
Irritable Bowel Syndrome I: Introduction
244
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
244
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
315
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
315


